Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy
Model scores of the 29,894 trials active now.
Model score 25% for any early termination, 15% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 21% of the time (131 trials).
Finished trial that started in 2015 or later: the model never saw it during training.
How it ended
Terminated on 2026-02-26, after 2023-04-18 start.
Reason given by the sponsor: “other”
The score above never used this outcome: finished trial that started in 2015 or later: the model never saw it during training.
Termination over time, as the model saw it at the start
Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2026-02-26. The rest of the way to 100% is still running.
From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.
What moved the score
-
Wording of the registration (title, summary, criteria) (raises risk) · Wording
Phrases that raised it: opioidpainpatients mustbowelcancer
Phrases that lowered it: participantstrialevaluateallergiesrandomized -
Sponsor's past termination rate: 20.7% (raises risk) · Sponsor's track record
-
Accepts healthy volunteers: No (raises risk) · Who can join
-
Minimum age: 40 (lowers risk) · Who can join
-
Disease area, cancer: Yes (raises risk) · Disease area
-
Has a data monitoring committee: Yes (raises risk) · Design
-
Trials the sponsor started in the prior 2 years: 113 (lowers risk) · Sponsor's track record
-
Sponsor type: academic or other (raises risk) · Sponsor's track record
-
Drug's FAERS reports with a death: 17.7% (lowers risk) · Drug's FDA history
-
Drug's FAERS reports marked serious: 78.4% (lowers risk) · Drug's FDA history
-
Disease area, neurology: Yes (raises risk) · Disease area
-
Phase: 2/3 (raises risk) · Design
-
Drug's FAERS reports before start: 974035 (lowers risk) · Drug's FDA history
-
Primary purpose: supportive care (lowers risk) · Design
-
Design: parallel (raises risk) · Design
-
Sponsor's past trials: 576 (raises risk) · Sponsor's track record
-
Drug's FAERS reports in the prior 12 months: 73671 (lowers risk) · Drug's FDA history
-
Maximum age: 75 (lowers risk) · Who can join
-
Drugs with FDA adverse-event history: 4 (lowers risk) · Drug's FDA history
-
Collaborators: 1 (raises risk) · Design
Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.
The trial
Design
- Phase
- 2/3 (typical: 2)
- Number of arms
- 2
- Allocation
- randomized
- Design
- parallel
- Primary purpose
- supportive care (typical: treatment)
- Blinding
- none
- Has a data monitoring committee
- Yes (typical: 56% yes)
- Responsible party
- sponsor
- Collaborators
- 1 (typical: 0)
- Keywords listed
- 0 (typical: 1)
Who can join
- Minimum age
- 40 (typical: 18)
- Maximum age
- 75 (typical: 71)
- Sex
- male (typical: all)
- Accepts healthy volunteers
- No (typical: 9% yes)
Sponsor's track record
- Sponsor type
- academic or other
- Sponsor's past trials
- 576 (typical: 32)
- Sponsor's past termination rate
- 20.7% (typical: 9.9%)
- Trials the sponsor started in the prior 2 years
- 113 (typical: 19)
Drug's FDA history
- Drugs with FDA adverse-event history
- 4 (typical: 1)
- Drug has FAERS history
- Yes (typical: 64% yes)
- Drug's FAERS reports before start
- 974035 (typical: 2148)
- Drug's FAERS reports in the prior 12 months
- 73671 (typical: 412.5)
- Drug's FAERS reports marked serious
- 78.4% (typical: 85.6%)
- Drug's FAERS reports with a death
- 17.7% (typical: 15.9%)
Disease area and drugs
- Disease areas
- cancer, neurology, urogenital
- Drugs matched to FDA substances
- acetaminophen, ketamine, ketorolac, oxycodone
Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.
Similar finished trials
- Postoperative Pain, Recovery and Discharge Following Robot-assisted Laparoscopic Prostatectomy NCT03639389 · started 2019 · scored riskier than 26% of active trials completed
- Perioperative Propranolol During Prostatectomy to Decrease Cancer Recurrence NCT05679193 · started 2023 · scored riskier than 34% of active trials completed
- IS-002 Phase 2 Prostate Cancer Study NCT05946603 · started 2023 · scored riskier than 96% of active trials completed
- Recovery From dNMB Using Different Sugammadex Doses in Elderly Patients Undergoing Robot-assisted Prostatectomy NCT04854993 · started 2021 · scored riskier than 12% of active trials completed
- Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy NCT00737893 · started 2017 · scored riskier than 94% of active trials completed
Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.